October was the biotech sector's worst month in 2013.
"Worst" is relative in an otherwise unbelievable year for biotech stocks, but as you can see from the chart above, our little corner of the market was beat by the S&P 500 in October.
June was the only other month this year during which the S&P 500 outperformed the biotech sector, but the broader market just lost less.
There are many reasons for the recent weakness in biotech stocks. As the year ends, some investors have definitely decided to lighten up on their winners.
was the best-performing stock between January and the end of September. And here's what Catalyst looked like in October:
I probably had
was the second-best performing stock January through September. And in October:
: Third-best return January through September. Not in October: nd
Picking up the pattern? Here's
, fourth best until Octoer:
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.